Thoughts on KEYNOTE-048

Thoughts on KEYNOTE-048

obr

4 months
89 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Danny Rischin, MD, Division of Cancer Medicine, Department of Medical Oncology, Peter MacCallum Cancer Centre, Professor of Medicine, University of Melbourne provides insight on KEYNOTE-048 investigating pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma.
Up Next Autoplay
Taking Baby Aspirin Improves  Overall Survival for Patients: What's Next For Research?
Taking Baby Aspirin Improves Overall Survival for Patients: What's Next For Research?
Category: Head and Neck Cancers
6 Views
Cancer-News 1 month
Why Is There No Benefit To Cancer Specific Survival?
Why Is There No Benefit To Cancer Specific Survival?
Category: Head and Neck Cancers
7 Views
Cancer-News 1 month
Taking Baby Aspirin Improves Overall Survival for Patients
Taking Baby Aspirin Improves Overall Survival for Patients
Category: Head and Neck Cancers
22 Views
Cancer-News 1 month
Taking Baby Aspirin Improves Overall Survival for Patients With Head & Neck, Lung Cancer
Taking Baby Aspirin Improves Overall Survival for Patients With Head & Neck, Lung Cancer
Category: Head and Neck Cancers
17 Views
Cancer-News 1 month
Cemiplimab in cSCC Updated Data
Cemiplimab in cSCC Updated Data
Category: Head and Neck Cancers
108 Views
obr 4 months
Importance of Stratification by PD-L1 Score
Importance of Stratification by PD-L1 Score
Category: Head and Neck Cancers
58 Views
obr 4 months
LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
Category: Head and Neck Cancers
16 Views
Annual-Meeting 5 months
Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).
Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).
Category: Head and Neck Cancers
308 Views
Annual-Meeting 5 months
Who Should Get Monotherapy Or Pembrolizumab Combo: Reasonable To Use Pembrolizumab Monotherapy In Patients That Have CPS Greater Than 20
Who Should Get Monotherapy Or Pembrolizumab Combo: Reasonable To Use Pembrolizumab Monotherapy In Patients That Have CPS Greater Than 20
Category: Head and Neck Cancers
44 Views
Annual-Meeting 5 months